Clinical Trial

Pulmonary Aspergillosis in Tuberculosis Patients

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 4, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Pulmonary tuberculosis (PTB) is the most common cause of lung destruction, contributing to coinfections development, and Aspergillosis spp. is one of the most important. Diagnosis of chronic pulmonary aspergillosis (CPA) in PTB patients is difficult due to similarity of clinical and radiological data, especially in resource-constrained settings. Differentiation of PTB patients with singling out a group with a higher Aspergillus IgG level during the initial examination will help physicians to orient to further examination of CPA. Objectives: to determine the prevalence of aspergillosis in Koch's bacillus-positive and Koch's bacillus-negative PTB patients and antifungal resistance of Aspergillus species isolates in Central Asia countries.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-09-06; most recent amendment 2025-04-01.
Trial Details
NCT Number NCT05045391
Lead Sponsor Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan
Conditions Pulmonary Tuberculoses, Aspergillosis, Old Tuberculosis, Active Tuberculosis, Chronic Pulmonary Aspergillosis
Enrollment 200 participants
Start Date 2020-01-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-04